GlassScriptPhysician profile
Andrew G Freeman
NPI 1306895198
$22,740.77
in general payments reported to CMS, 2019-2025
64 companies · $2,388 in 2025
The $2,388 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,810 · 2020: $2,230 · 2021: $2,779 · 2022: $2,717 · 2023: $7,375 · 2024: $3,441 · 2025: $2,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,153 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,520 · Travel and Lodging: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,152.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,520.00 |
| Travel and Lodging | $530.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $4,410.77 | 2023-2025 | Azstarys, Adlarity |
| Abbvie INC. | $2,093.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,028.70 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,748.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,565.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,148.59 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $766.07 | 2021-2025 | |
| Amgen INC. | $763.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $575.55 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $472.94 | 2019-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $465.38 | 2019-2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $402.93 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $386.33 | 2020-2023 | Belsomra, Gardasil 9, Vaxneuvance |
| Paratek Pharmaceuticals, INC. | $384.09 | 2023-2024 | Nuzyra |
| Genentech USA, INC. | $362.57 | 2020-2021 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $311.72 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.58 | 2019-2025 | |
| Axsome Therapeutics, INC. | $293.09 | 2023-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $286.32 | 2022-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Novartis Pharmaceuticals Corporation | $262.56 | 2019-2024 | |
| Antares Pharma, INC. | $242.28 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Corcept Therapeutics | $226.13 | 2020-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $220.74 | 2019-2025 | Spravato, Xarelto |
| Lundbeck LLC | $196.71 | 2024-2025 | Vyepti, Rexulti |
| Esperion Therapeutics, INC. | $189.73 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $180.70 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $179.33 | 2019-2025 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $176.16 | 2020-2021 | |
| Madrigal Pharmaceuticals | $148.43 | 2024 | Rezdiffra |
| Mylan Specialty L.P. | $145.23 | 2019-2024 | Yupelri |
| Ironshore Pharmaceuticals INC. | $143.91 | 2019-2020 | |
| Amarin Pharma, INC. | $132.92 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $131.06 | 2022 | |
| Jazz Pharmaceuticals INC. | $123.03 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $121.85 | 2019-2022 | |
| Astellas Pharma US INC | $99.02 | 2019-2025 | Veozah |
| Eisai INC. | $78.02 | 2020-2022 | |
| Neos Therapeutics, LP | $72.06 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $70.44 | 2020-2022 | |
| Abbott Laboratories | $60.70 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Daiichi Sankyo INC. | $59.91 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $57.38 | 2019-2024 | Kloxxado, Ryaltris, Mitigare |
| Optinose US, INC. | $54.96 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $50.72 | 2023-2024 | Quviviq |
| Inspire Medical Systems, INC. | $49.56 | 2025 | Inspire |
| Sanofi Pasteur INC. | $48.68 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.57 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $44.70 | 2019-2021 | Xyosted |
| Shire North American Group INC | $38.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.44 | 2019-2020 | |
| Ibsa Pharma INC. | $33.45 | 2023-2024 | Tirosint, Tirosint, Licart |
| Tolmar, INC. | $32.67 | 2024 | |
| Sumitomo Pharma America, INC. | $31.89 | 2025 | Gemtesa |
| Boston Scientific Corporation | $23.59 | 2025 | Wavewriter Alpha Prime 16 |
| Xeris Pharmaceuticals, INC. | $19.75 | 2023 | Gvoke Hypopen |
| Aytu Biopharma, INC. | $18.43 | 2024 | Karbinal |
| Celgene Corporation | $17.69 | 2019 | |
| Medtronic, INC. | $17.62 | 2023 | Intellis Adaptivestim |
| Halozyme INC | $15.57 | 2023 | |
| Endo Pharmaceuticals INC. | $14.85 | 2020 | |
| Bausch Health US, LLC | $14.84 | 2022 | |
| Clarus Therapeutics INC. | $14.38 | 2021 | |
| Upsher-Smith Laboratories LLC | $13.07 | 2021 | |
| Impel Pharmaceuticals INC. | $13.07 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.